29 Май, 2003
Antipsychotic drugs may reduce diabetes risk in mentally ill - Psychosis
Two related University at Buffalo studies examining the incidence of diabetes and related conditions among patients suffering from schizophrenia or bipolar disorder indicate that it is the illness - not the atypical antipsychotic medications used to treat the disorders - that contributes to the increased incidence of diabetes in these patients. Drug Week via NewsEdge Corporation : Two related University at Buffalo (UB) studies examining the incidence of diabetes and related conditions among patients suffering from schizophrenia or bipolar disorder indicate that it is the illness - not the atypical antipsychotic medications used to treat the disorders - that contributes to the increased incidence of diabetes in these patients. The findings suggest that the atypical antipsychotics, second-generation antipsychotic medications that became available after 1991, such as Clozaril (clozapine), Zyprexa (olanzapine), Risperdal (risperidone) and Seroquel (quetiapine fumarate), may actually have a protective effect against diabetes. The results seem to contradict growing fears that antipsychotic medications cause the increased rate of diabetes in patients with these mental illnesses, fears that recently led Japan and the European Union to require one atypical antipsychotic to include warnings about diabetes-related complications in its product information sheets. The studies were conducted by researchers in the department of pharmacy practice in the UB School of Pharmacy and Pharmaceutical Sciences. One study was presented in a poster session at the annual conference of the College of Psychiatric and Neurologic Pharmacists in Charleston, South Carolina. The other was presented in a poster session at the annual conference of the American Psychiatric Association in San Francisco. Based on the findings, the UB researchers concluded that psychiatric care for patients with the two disorders should be modified to include routine screening for diabetes (type 2), hypertension and obesity. They also suggested that severe mental illness should be listed, along with family history of diabetes, as a primary risk factor for diabetes. "According to our findings in these studies, an association between schizophrenia and bipolar disorder and diabetes seems to exist independent of any antipsychotic use," said Terrance Bellnier, RPh, assistant clinical professor of pharmacy practice, director of psychiatric pharmacy practice at UB and coauthor of the study. "The question is, whether these drugs induce diabetes at the same rate, or it's the mental illness itself - what we're using the drugs for - that induces diabetes," Bellnier said. "That's the question we tried to answer." More than 2 million Americans suffer from schizophrenia and the same number suffer from bipolar disorder. Diabetes is estimated to affect more than 15 million Americans. Data in the study presented at the annual conference of the American Psychiatric Association demonstrate that an increased incidence of diabetes among patients with schizophrenia or bipolar disorder predates the use of antipsychotic medications to treat the disorders. That study, based on a retrospective review of medical data for 569 randomly selected patients with the two disorders admitted to a state psychiatric hospital between 1940 and 1950, before antipsychotic medications were available, found that metabolic disturbances were significantly greater in those patients than among the general population. According to the results, the rate of diabetes among the patients was 20.9%, or 10 times that reported at that time for the general population. The incidence of hypertension was 29.1%, compared to 16.5% in the general population, and the incidence of "overweight" was 28.2% versus 21.8% in the general population. The other UB study compared in a matched-pair analysis the data for these untreated patients with data from 569 patients admitted to a state psychiatric hospital between 1999 and 2002, all of whom were treated with atypical antipsychotics. In patients treated with the medications, the rate of diabetes was 10.4%, half of what was reported in the group that received no medication, and slightly more than twice the rate reported in the general population. The second study also found that the incidence of hypertension in the treated patients was 15.6%, compared to 7.2% in the general population, while hypertension in the untreated population was nearly twice as prevalent. "When you effectively treat schizophrenia and bipolar disorder, you reduce most of these other metabolic risk factors," said Bellnier. "While the incidence of diabetes has actually gone up in the general population since the 1940s and 1950s, our study shows it has gone down significantly in patients being treated with antipsychotic medications, so these antipsychotic drugs may actually have a protective effect," he said. According to Bellnier, it is possible that hypercortisolemia, the elevated levels of cortisol - the hormone secreted by the adrenal gland in response to stress - may contribute to metabolic syndrome in severely mentally ill patients. "When you effectively treat these disorders and therefore reduce the psychotic and manic episodes associated with the elevation of cortisol, then you may also be protecting them from diabetes," he said. According to the study's authors, one metabolic disturbance did increase with the use of antipsychotic medications and that was the incidence of patients considered overweight. While untreated patients had an incidence of "overweight" of 28.2%, vs. 21.8% in the general population at that time, the incidence of "overweight" in the treated population was 68.6%, compared to 37% in the general population at that time. Bellnier said this striking statistic provides strong evidence of a connection between the use of multiple psychotrophics, such as antipsychotics, antidepressants, mood stabilizers and anticonvulsants, and the incidence of overweight in severely mentally ill patients. Still, he noted, this single metabolic disturbance does not account for the incidence of diabetes among these patients. "Obesity alone does not explain it. You can be heavy for years and not develop diabetes," he said. Based on their findings, the UB researchers concluded that psychiatric care should be modified to include routine screening for diabetes, hypertension and obesity. "An enormous amount of energy has been wasted in trying to blame one drug over another as the cause of this higher risk," said Bellnier. "What we need to do now is to raise the bar a little in caring for these patients so that they now receive the same routine screening for diabetes and related conditions that the general population receives." According to Bellnier, advocates for the mentally ill have, for good reason, focused primarily on good psychiatric care. "But we've moved into an era where that care is available," said Bellnier. "These patients are predisposed to metabolic disturbances and they deserve the same care that everyone else gets. And ultimately, when they start getting preventive care or treatment for these conditions, instead of emergency care because their diabetes has never been treated, there will be a major economic benefit to the health care system as well." Funded by UB, the studies were coauthored by Bellnier's postdoctoral fellow, Adam Decatur, PharMD; Kashinath Patil, MD, assistant clinical professor, department of psychiatry, University of Rochester, and Tulio Ortega, MD, adjunct assistant clinical professor, UB department of pharmacy practice. This article was prepared by Drug Week editors from staff and other reports. <> << Copyright ©2003 NewsRx.com >>
27 Май, 2003
VI Научная конференция молодых ученых посвященная памяти академика А.В. Снежневского

27 мая 2003 года состоится VI научная конференция молодых ученых посвященная памяти академика А.В. Снежневского.

Председатели: академик РАМН А.С.Тиганов, проф. Д.Д.Орловская

Программа конференции.

10.30-11.00 Вступительное слово академика РАМН, профессора А.С. Тиганова.

11.00-11.15 Сюняков Т.С. К проблеме сдвоенных психогенно спровоцированных аффективных фаз при реактивной шизофрении.

11.15-11.30 Иконников Д.В. Реакции капитуляции у больных шизофренией (клинические аспекты.

11.30-11.45 Бурлаков А.В. Психические расстройства в предоперационном периоде аорто-коронарного шунтирования.

11.45-12.00 Самушия М.А. Психические расстройства в отдаленном периоде аорто-коронарного шунтирования (психопатология, психосоматические корреляции, прогностическое значение).

12.00-12.15 Медведев В.Э. Сезонные аффективные расстройства у больных вялотекущей шизофренией.

12.15-12.30 Крылова Е.С. Клинико-психопатологические и терапевтические аспекты юношеских депрессий с симптомокомплексом «метафизической интоксикации».

12.30-12.45 Красноперова М.Г. Манифестный инфантильный психоз, завершающийся формированием дефицитарных состояний типа детского аутизма (клинико-психопатологические особенности, типология).

12.45-13.00 Этингоф A.M. Клинико-психопатологические особенности юношеских дисморфофобических депрессий.

13.00-13.15 Шмакова О.П. Особенности школьной адаптации детей и подростков с психическими расстройствами.

13.15-13.30 Щеглова Е.Ю. Катамнез депрессивных эпизодов, впервые возникших в позднем возрасте.

13.30-13.45 Михайлова И.И. Виды самостигматизации психически больных.

13.45-14.00 Серебрийская Л.Я. Стереотипы психического заболевания в общественном сознании.

14.00-14.15 Степанова А.Ф. Потребность пациентов ПНД в психосоциальных формах помощи.

Конференция состоится в здании НЦПЗ РАМН по адресу: 115522 Москва, Каширское шоссе 34

13 Май, 2003
New, more convenient form of leading schizophrenia medication Risperdal now available.
A new, fast-dissolving form of the schizophrenia medication Risperdal will be launched during the second week of May 2003. Risperdal M-Tab dissolves in seconds when placed on the tongue. Chemical Business NewsBase - Press Release via NewsEdge Corporation : A new, fast-dissolving form of the schizophrenia medication Risperdal (risperidone) will be launched during the second week of May 2003. Risperdal M-Tab dissolves in seconds when placed on the tongue. Risperdal, marketed by Janssen Pharmaceutica Products LP, is the most widely prescribed antipsychotic medication in the US. Risperdal M-Tab tablets are produced using freeze-drying technology, creating highly porous tablets that rapidly disintegrate upon contact with saliva. The coral-coloured, peppermint-flavoured tablets will be available in 0.5 mg, 1 mg and 2 mg doses and are bioequivalent to comparable dosages of the original-formulation tablets. In clinical trials, Risperdal was generally well tolerated. Based in Titusville, NJ, Janssen Pharmaceutica Products LP, a wholly owned subsidiary of Johnson & Johnson, has a long track record in developing and marketing treatments for central nervous system disorders. Publication: Chemical Business NewsBase - Press Release Distributed by Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>
12 Май, 2003
Magnet therapy silences schizoid mind's voices
: The movie 'A Beautiful Mind' portrays Nobel laureate John Nash's schizophrenia as a series of ominous hallucinations- an imaginary student occupies the mathematician's undergraduate rooms at Princeton, imaginary spies trail him around on the campus and .. The Economic Times via NewsEdge Corporation : : The movie 'A Beautiful Mind' portrays Nobel laureate John Nash's schizophrenia as a series of ominous hallucinations- an imaginary student occupies the mathematician's undergraduate rooms at Princeton, imaginary spies trail him around on the campus and equally imaginary operatives sit him down in elaborate, science-fiction-style rooms to give him orders that only he can hear. Audiences all over the world loved the movie, which went on to win four Oscars. However, mental health experts had a different take. Dr Fuller Torrey, author of the best-selling 'Surviving Schizophrenia', for instance, said, "If someone walked into a room with the kind of s y m p t o m s shown in the movie, all of us in the business would send him for an MRI to see if he had a brain tumour, or had a reaction to a drug or something. (For what was shown) was not a real version of schizophrenia, it was Hollywood's version.'' More pertinently, recent research suggests that the hallucinations that were the bane of John Nash's beautiful mind could be relieved by an experimental procedure that directs magnetic waves toward certain brain regions. Scientists led by psychiatrist Ralph E. Hoffmann of Yale University report in a recent issue of Archives of General Psychiatry' that of 12 patients who received up to 16 minutes of magnetic stimulation for nine days, nine said their hallucinations had improved. People reported that they were hearing voices less often and were less disturbed by such hallucinations when they did appear. In contrast, similar improvements were reported by only two of the 12 participants who had a placebo treatment that involved a similar procedure, but not magnetic stimulation. Dr Hoffman and his colleagues said they zeroed in on hallucinations because they believed them to be "critical, core experiences that really constitute what having schizophrenia is all about''. They also believe that schizophrenia causes a loss of gray matter that intensifies the link between the brain region involved in speech production (Broca's area) with that of speech perception (Wernicke's Area). Magnetic therapy seemed to work by calming the nerves that, under other circumstances, would become excited and lead people to hallucinate. As many as 50 per cent to 75 per cent of schizophrenia patients report hearing voices that are not there. These may be voices that whisper to the person, command them to do things, comment on their actions or even suggest courses of action-haranguing, insulting and sometimes provoking the patients to violence or even suicide. The voices can be from people they know (a dead relative) or strangers. However, despite their widespread prevalence, auditory hallucinations have traditionally been dismissed as 'crazy talk' by doctors treating schizophrenia. While medication does help in many cases, as many as 25 per cent of schizophrenics with auditory hallucinations show only partial or no improvement with drugs. The patients in the current study, for instance, heard voices in their head up to five times a day before magnetic therapy. (One patient who committed suicide described her voices as 'a constant state of mental rape'.) The researchers targeted the magnetic beams to brain regions that previous studies have indicated play a critical role in auditory hallucinations. In earlier research, Dr Hoffman and his colleagues had some success in quieting auditory hallucinations in schizophrenics who received a shorter course of magnetic therapy, lasting only four days. However, all the patients who improved after four days of treatment had a resurgence of symptoms anywhere from four days to two months after treatment. In the current study, more than half of the patients maintained their improvements for at least 15 weeks. "However, in both groups, it may be necessary to repeat the procedure." Dr Hoffmann also emphasised that the technique was still experimental and needed to be critically evaluated before being made available to patients. Publication: The Economic Times Distributed by Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>
10 Май, 2003
Ziprasidone demonstrates fast onset of action in significantly reducing symptoms - Bipolar Disorder
Bipolar patients who received Pfizer, Inc.'s atypical antipsychotic ziprasidone showed significant improvement in symptoms of acute mania compared with those who received placebo, according to new data. Drug Week via NewsEdge Corporation : Bipolar patients who received Pfizer, Inc.'s atypical antipsychotic ziprasidone showed significant improvement in symptoms of acute mania compared with those who received placebo, according to new data. Results from this randomized, double-blind, placebo-controlled study demonstrated that ziprasidone produced rapid, sustained improvements in manic symptoms when compared to placebo. Significant improvements were observed within 2 days of treatment and were maintained throughout the 3-week study. The study, which involved 210 inpatients, also demonstrated that after 7 days of treatment ziprasidone-treated patients showed significant improvement across all evaluation scales compared to those who took placebo, including symptoms of acute mania, psychosis and social functioning. It was published in the American Journal of Psychiatry. "Physicians are often looking for effective treatment options to help control the multiple symptoms of acute mania in patients who suffer from bipolar disorder," said Dr. Paul Keck, professor of psychiatry and pharmacology and vice chairman for research, department of psychiatry, University of Cincinnati College of Medicine. "This study suggests that ziprasidone may be a rapid and beneficial treatment option for bipolar mania." Bipolar disorder, which is also referred to as manic-depressive illness, is a serious form of mood disorder in which patients may experience extreme "highs," or manic episodes, and extreme "lows," or periods of major depression. The condition is estimated to affect 1 in every 100 Americans and has a major impact on the ability to function in daily life. Bipolar disorder is estimated to cost society about $45 billion per year. Patients in the midst of a period of mania, which usually lasts at least a week, may appear to be overly energetic, extremely expansive or excessively happy. They may have difficulty sleeping, functioning in social or work situations and may overindulge in pleasurable activities. The study was conducted in the United States and Brazil. Ziprasidone patients began taking 80 mg per day and were quickly titrated to 160 mg per day by the second day. Dosing was then flexible for the remainder of the study. Efficacy was measured using standardized psychiatric assessment scales. Among ziprasidone-treated patients, there was a low incidence of movement disorders, a side effect associated with some atypical antipsychotic medications and no clinically significant weight gain, changes in vital signs or other safety parameters (Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry, 2003;160(4):741-8). The most common side effects of ziprasidone in this study included somnolence, headache, dizziness, hypertonia, nausea and akathisia. Discovered and developed by Pfizer, ziprasidone is a serotonin and dopamine antagonist. The medicine was approved by the U.S. Food and Drug Administration in February 2001 for use in the treatment of schizophrenia. It also is approved in more than 45 countries worldwide. Ziprasidone received approval for the treatment of acute mania in Brazil in November 2002. Pfizer plans to file a supplemental new drug application FDA later this year for the treatment of acute mania. Ziprasidone is currently marketed as Geodon in the United Sates and in Brazil. This article was prepared by Drug Week editors from staff and other reports. <> << Copyright ©2003 NewsRx.com >>
06 Май, 2003
Zyprexa demonstrates superior long-term efficacy in treating schizophrenia, new data show.
In a head-to-head study comparing two atypical antipsychotic treatments for schizophrenia, Zyprexa was shown to have greater efficacy than Geodon . The results of the 28-week, double-blind, flexible-dose study were presented this week at a major international psychiatric congress. Chemical Business NewsBase - Press Release via NewsEdge Corporation : In a head-to-head study comparing two atypical antipsychotic treatments for schizophrenia, Zyprexa (olanzapine, Lilly) was shown to have greater efficacy than Geodon (ziprasidone, Pfizer). The results of the 28-week, double-blind, flexible-dose study were presented this week at a major international psychiatric congress.. Long-term treatment with Zyprexa resulted in significantly better improvement in treating positive symptoms (delusions and hallucinations), as well as negative symptoms (diminished emotion, lack of interest and depressive signs), on all efficacy measures. Also, significantly more Zyprexa patients responded positively to treatment (58.6% versus 42.5%). A significantly greater proportion of Geodon patients also required a dose reduction because of side-effects. Publication: Chemical Business NewsBase - Press Release Distributed by Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>
28 Апрель, 2003
Диссертации:

на заседании диссертационного совета НЦПЗ РАМН состоялась защита кандидатской диссертации

23 Апрель, 2003
Конференция "Болезнь Альцгеймера и старение"

Глубокоуважаемые господа!

Приглашаем Вас принять участие в работе Третьей Российской конференции с международным участием "Болезнь Альцгеймера и старение", посвящённой 100-летию со дня рождения проф. Э.Я.Штернберга. Конференция состоится 23 апреля 2003 года в 10.00 в конференц-зале Научного центра психического здоровья РАМН. Она будет посвящена одной из приоритетных проблем современной психоневрологии - болезни Альцгеймера. В 4х научных заседаниях будут освещены следующие аспекты нейродегенеративных заболеваний: нейробиологические и в том числе молекулярно-генетические основы болезни Альцгеймера; патогенетические механизмы нейродегенеративных заболеваний; поиск диагностических маркеров болезни Альцгеймера. Особое внимание будет уделено современным медико-биологическим подходам к направленному поиску лекарственных средств для предупреждения и лечения болезни Альцгеймера, а также особенностям терапии на разных этапах её течения.

В период проведения конференции будет работать выставка, в которой примут участие ведущие фармацевтические фирмы, будут распространяться информационные материалы по диагностике и лечению болезни Альцгеймера.

Конференция состоится в здании НЦПЗ РАМН по адресу: 115522 Москва, Каширское шоссе 34

Контактный телефон оргкомитета конференции (095)324-96-15 , Факс: (095) 324-51-84 , e-mail: gavrilova@donis.iasnet.ru

Заместитель председателя Оргкомитета Конференции
Руководитель отдела по изучению болезни Альцгеймера
и ассоциированных с ней расстройств НЦПЗ РАМН,
профессор С.И.Гаврилова

22 Апрель, 2003
Конференция "Современные аспекты клиники и терапии эндогенных психических расстройств".

Санкт-Петербургский научно-исследовательский институт им. В.М.Бехтерева и общества психиаторов Санкт-Петербурга и Ленинградской области проводят юбилейную научно-практическую конференцию "Современные аспекты клиники и терапии эндогенных психических расстройств", посвещенной 75-летию со дня рождения Заслуженного деятеля науки Российской Федерации, профессора Руслана Яковлевича Вовина. Конференция состоится 22 апреля 2003 года в НИПНИ им. В.М. Бехтерева. По теме конференции будет проведено пленарное заседание и круглый стол "Новые возможности в лечении психических заболеваний с применением современных психотропных лекарственных средств". Материалы конференции будут изданы в сборнике "Современные аспекты клиники и терапии эндогенных психических расстройств".

Требования по предоставлению материалов для публикации:

Тезисы объемом не более 2-х страниц формата А4, шрифт Times New Roman, размер 12 п., 1,5 интервала принимаются по электронной почте spbinstb@infopro.spb.ru , либо на компьютерной дискете 3,5" вместе с отпечатанным вариантом (для почтовых отправлений обязательна пометка "в адрес Оргкомитета конференции").

Сроки подаци заявок до 20 февраля 2003 года.

Почтовый адрес: 198019, Россия, Санкт-Питербург, ул. бехтерева, д.3, Научно-исследовательский психоневрологический институт им. В.М. Бехтерева.

Тел: (812) 567-71-28, 567-72-26, 567-90-48

Факс: (812) 567-90-48

 

17 Апрель, 2003
Atypical antipsychotics may be associated with developing glucose intolerance - New-Onset Diabetes
"Certain atypical antipsychotics may be associated with new-onset glucose intolerance, including acute diabetes and ketoacidosis," concludes a new study. Pain & Central Nervous System Week via NewsEdge Corporation : "Certain atypical antipsychotics may be associated with new-onset glucose intolerance, including acute diabetes and ketoacidosis," concludes a new study. Creighton University psychiatrists collected data from the Ohio Department of Mental Health database on patients treated with an atypical antipsychotic and treated or evaluated from diabetes. "Blood glucose levels, glucose tolerance, or other evaluations of diabetes had been conducted in 14 of the 126 patients treated with atypical antipsychotics," D.R. Wilson and colleagues found. They reported that "in 11 of the 14, new-onset, acute, and marked glucose intolerance developed after treatment with clozapine, olanzapine, or quetiapine. Of these, six patients required insulin therapy (four only transiently) and five patients developed diabetic ketoacidosis (DKA). "Also, glucose metabolism was labile in all cases, and was transient in two cases with subsequent resolution despite on-going antipsychotic therapy," the researchers said. They concluded, "Monitoring for changes in blood glucose levels in patients taking atypical antipsychotics may be indicated. More systematic study data are clearly needed." Wilson and colleagues published the results of their study in Schizophrenia Research (New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res, 2003;59(1):1-6). The corresponding author for this report is D.R. Wilson, Creighton University, School of Medicine, Department Psychiatry, 3528 Dodge St., Omaha, NE 68131, USA. To subscribe to the journal Schizophrenia Research, contact the publisher: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands. The information in this article comes under the major subject areas of Adverse Drug Effects, Diabetes, Schizophrenia, New-Onset Glucose Intolerance, Ketoacidosis. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. <> << Copyright ©2003 NewsRx.com >>